CN102007106B - 3-取代的-1，4-二氮杂卓-2-酮黑皮质素-5受体拮抗剂 - Google Patents
3-取代的-1，4-二氮杂卓-2-酮黑皮质素-5受体拮抗剂 Download PDFInfo
- Publication number
- CN102007106B CN102007106B CN200980113158.7A CN200980113158A CN102007106B CN 102007106 B CN102007106 B CN 102007106B CN 200980113158 A CN200980113158 A CN 200980113158A CN 102007106 B CN102007106 B CN 102007106B
- Authority
- CN
- China
- Prior art keywords
- group
- methyl
- oxo
- optionally substituted
- diazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *N(*C(C1)([C@@]1CN1)NC2(CC2)C1=O)c1ccccc1 Chemical compound *N(*C(C1)([C@@]1CN1)NC2(CC2)C1=O)c1ccccc1 0.000 description 3
- DLQDJBSUJNUBQX-UHFFFAOYSA-N CC(C)(C)OC(NCC(C=C)=O)=O Chemical compound CC(C)(C)OC(NCC(C=C)=O)=O DLQDJBSUJNUBQX-UHFFFAOYSA-N 0.000 description 1
- DNHNBMQCHKKDNI-SECBINFHSA-N CC[C@H](CO)c1ccccc1 Chemical compound CC[C@H](CO)c1ccccc1 DNHNBMQCHKKDNI-SECBINFHSA-N 0.000 description 1
- DNWDDXKKRDRWLI-ZCYQVOJMSA-N NC[C@H](CCN1CC(c2ccccc2)c2ccccc2)N[C@@H](Cc2ncccc2)C1=O Chemical compound NC[C@H](CCN1CC(c2ccccc2)c2ccccc2)N[C@@H](Cc2ncccc2)C1=O DNWDDXKKRDRWLI-ZCYQVOJMSA-N 0.000 description 1
- YDNYFVLZWYCBQI-SMCANUKXSA-N O=CC[C@@H]1N[C@H](CNC(c(cc2)cc(cc3)c2cc3F)=O)CCN(CC(c2ccccc2)c2ccccc2)C1=O Chemical compound O=CC[C@@H]1N[C@H](CNC(c(cc2)cc(cc3)c2cc3F)=O)CCN(CC(c2ccccc2)c2ccccc2)C1=O YDNYFVLZWYCBQI-SMCANUKXSA-N 0.000 description 1
- SRISHMVSUHENAI-UHFFFAOYSA-N OC(c(cc1)cc(cc2)c1cc2Cl)=O Chemical compound OC(c(cc1)cc(cc2)c1cc2Cl)=O SRISHMVSUHENAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3289808P | 2008-02-29 | 2008-02-29 | |
| US61/032,898 | 2008-02-29 | ||
| PCT/AU2009/000232 WO2009105825A1 (en) | 2008-02-29 | 2009-02-27 | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102007106A CN102007106A (zh) | 2011-04-06 |
| CN102007106B true CN102007106B (zh) | 2014-09-03 |
Family
ID=41015442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980113158.7A Expired - Fee Related CN102007106B (zh) | 2008-02-29 | 2009-02-27 | 3-取代的-1，4-二氮杂卓-2-酮黑皮质素-5受体拮抗剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8440653B2 (enExample) |
| EP (1) | EP2257533B1 (enExample) |
| JP (1) | JP5503559B2 (enExample) |
| KR (1) | KR101620116B1 (enExample) |
| CN (1) | CN102007106B (enExample) |
| AU (1) | AU2009219108B2 (enExample) |
| BR (1) | BRPI0907898B8 (enExample) |
| CA (1) | CA2716256C (enExample) |
| ES (1) | ES2439964T3 (enExample) |
| IL (1) | IL207701A (enExample) |
| MX (1) | MX2010009486A (enExample) |
| NZ (1) | NZ587362A (enExample) |
| RU (1) | RU2524245C2 (enExample) |
| WO (1) | WO2009105825A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485725B2 (en) | 2017-12-15 | 2022-11-01 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5503558B2 (ja) * | 2008-02-29 | 2014-05-28 | ミメチカ ピーティーワイ エルティーディー | Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療 |
| WO2016149628A1 (en) * | 2015-03-19 | 2016-09-22 | Chembridge Corporation | Tgr5 agonists |
| CN116262115A (zh) * | 2021-12-15 | 2023-06-16 | 深圳先进技术研究院 | 释放氨基酸及其衍生物类药物的医用材料及其应用方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999048913A1 (en) * | 1998-03-24 | 1999-09-30 | The University Of Queensland | Peptide turn mimetics |
| WO2003013571A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| WO2008017852A1 (en) * | 2006-08-11 | 2008-02-14 | Palatin Technologies, Inc. | Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL204753B1 (pl) * | 2000-05-25 | 2010-02-26 | Hoffmann La Roche | Podstawiony 1-aminoalkilolaktam , zawierający go środek farmaceutyczny, sposób wytwarzania podstawionego 1-aminoalkilolaktamu i jego zastosowanie |
| US6916812B2 (en) | 2001-10-09 | 2005-07-12 | Bristol-Myers Squibb Company | Alpha-aminoamide derivatives as melanocortin agonists |
| AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
| JP5503558B2 (ja) * | 2008-02-29 | 2014-05-28 | ミメチカ ピーティーワイ エルティーディー | Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療 |
-
2009
- 2009-02-27 EP EP09716109.5A patent/EP2257533B1/en not_active Not-in-force
- 2009-02-27 US US12/919,973 patent/US8440653B2/en not_active Expired - Fee Related
- 2009-02-27 AU AU2009219108A patent/AU2009219108B2/en not_active Ceased
- 2009-02-27 CA CA2716256A patent/CA2716256C/en not_active Expired - Fee Related
- 2009-02-27 NZ NZ587362A patent/NZ587362A/en not_active IP Right Cessation
- 2009-02-27 ES ES09716109.5T patent/ES2439964T3/es active Active
- 2009-02-27 RU RU2010137033/04A patent/RU2524245C2/ru active
- 2009-02-27 JP JP2010547919A patent/JP5503559B2/ja not_active Expired - Fee Related
- 2009-02-27 WO PCT/AU2009/000232 patent/WO2009105825A1/en not_active Ceased
- 2009-02-27 MX MX2010009486A patent/MX2010009486A/es active IP Right Grant
- 2009-02-27 BR BRPI0907898A patent/BRPI0907898B8/pt not_active IP Right Cessation
- 2009-02-27 CN CN200980113158.7A patent/CN102007106B/zh not_active Expired - Fee Related
- 2009-02-27 KR KR1020107021385A patent/KR101620116B1/ko not_active Expired - Fee Related
-
2010
- 2010-08-19 IL IL207701A patent/IL207701A/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999048913A1 (en) * | 1998-03-24 | 1999-09-30 | The University Of Queensland | Peptide turn mimetics |
| WO2003013571A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| WO2008017852A1 (en) * | 2006-08-11 | 2008-02-14 | Palatin Technologies, Inc. | Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485725B2 (en) | 2017-12-15 | 2022-11-01 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0907898B8 (pt) | 2021-05-25 |
| RU2010137033A (ru) | 2012-04-10 |
| AU2009219108A1 (en) | 2009-09-03 |
| WO2009105825A1 (en) | 2009-09-03 |
| EP2257533B1 (en) | 2013-09-18 |
| CA2716256C (en) | 2016-08-23 |
| AU2009219108B2 (en) | 2013-11-21 |
| KR20100126440A (ko) | 2010-12-01 |
| BRPI0907898A2 (pt) | 2018-05-22 |
| RU2524245C2 (ru) | 2014-07-27 |
| ES2439964T3 (es) | 2014-01-27 |
| BRPI0907898B1 (pt) | 2020-09-29 |
| HK1149255A1 (en) | 2011-09-30 |
| JP2011514339A (ja) | 2011-05-06 |
| IL207701A (en) | 2017-04-30 |
| EP2257533A1 (en) | 2010-12-08 |
| EP2257533A4 (en) | 2011-05-11 |
| US20110059952A1 (en) | 2011-03-10 |
| NZ587362A (en) | 2012-06-29 |
| JP5503559B2 (ja) | 2014-05-28 |
| US8440653B2 (en) | 2013-05-14 |
| CN102007106A (zh) | 2011-04-06 |
| MX2010009486A (es) | 2011-02-22 |
| IL207701A0 (en) | 2010-12-30 |
| CA2716256A1 (en) | 2009-09-03 |
| KR101620116B1 (ko) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2257297B1 (en) | Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion | |
| CN102007105B (zh) | 3-氨基烷基-1,4-二氮杂环庚烷-2-酮黑皮质素-5受体拮抗剂 | |
| CN102007106B (zh) | 3-取代的-1，4-二氮杂卓-2-酮黑皮质素-5受体拮抗剂 | |
| US20130225563A1 (en) | Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor | |
| HK1149255B (en) | 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists | |
| US8343958B2 (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists | |
| HK1149187A (en) | Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion | |
| HK1149187B (en) | Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion | |
| HK1148730B (en) | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Vitoria, Australia Applicant after: Mimetica Pty Ltd. Address before: Queensland, Australia Applicant before: Mimetica Pty Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |